L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and
death. An overactive sympathetic nervous system in CKD patients is one of the major
mechanisms increasing the cardiovascular risks in this patient population. A potential signal
driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide
synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a
strong, independent predictor of future cardiovascular events in these patients. .
The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA
with acute L-arginine infusion reduces SNA in CKD patients.